文献速递骨软组织肉瘤与黑色素瘤

基于病理缓解的可切除III/IV期皮肤黑色素瘤新辅助帕博利珠单抗治疗的长期结局

Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.
PubMed 文献 · Ann Oncol · 2023-07-04

本研究是对一项已发表的Ib期临床试验的随访研究,纳入了30例可切除III/IV期皮肤黑色素瘤患者,术前3周接受单次200 mg静脉新辅助帕博利珠单抗,术后接受1年辅助帕博利珠单抗治疗。中位随访61.9个月,主要结局为5年总生存(OS)、5年无复发生存(RFS)及复发模式。

要点

  • 主要病理缓解(MPR,存活肿瘤<10%)或完全病理缓解(pCR,无存活肿瘤)患者(n=8)无死亡发生。
  • 其余队列的5年OS为72.8%(P=0.12)。
  • pCR或MPR患者中8例有2例复发;存活肿瘤>10%的患者中22例有8例(36%)复发。

核心结论

  • 新辅助治疗后反应持续是OS和RFS的重要预后因素。
  • 达到pCR的患者复发较晚且可挽救,5年OS为100%。
  • 这些结果证明了单药新辅助/辅助PD-1阻断在pCR患者中的长期疗效,以及对这些患者进行长期随访的重要性。

研究设计与样本

  • 本研究是对一项已发表的Ib期临床试验的随访研究,纳入30例可切除III/IV期皮肤黑色素瘤患者。
  • 患者术前3周接受单次200 mg静脉新辅助帕博利珠单抗,术后接受1年辅助帕博利珠单抗治疗。
  • 主要结局为5年OS、5年RFS和复发模式。

主要发现

  • 中位随访61.9个月,5年随访更新结果。
  • MPR(存活肿瘤<10%)或pCR(无存活肿瘤)患者(n=8)无死亡发生,其余队列的5年OS为72.8%(P=0.12)。
  • pCR或MPR患者中8例有2例复发;存活肿瘤>10%的患者中22例有8例(36%)复发。
  • 存活肿瘤≤10%患者的中位复发时间为3.9年,存活肿瘤>10%患者为0.6年(P=0.044)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While neoadjuvant immunotherapy for melanoma has shown promising results, the data have been limited by a relatively short follow-up time, with most studies reporting 2-year outcomes. The goal of this study was to determine long-term outcomes for stage III/IV melanoma patients treated with neoadjuvant and adjuvant programmed cell death receptor 1 (PD-1) inhibition. PATIENTS AND METHODS: This is a follow-up study of a previously published phase Ib clinical trial of 30 patients with resectable stage III/IV cutaneous melanoma who received one dose of 200 mg IV neoadjuvant pembrolizumab 3 weeks before surgical resection, followed by 1 year of adjuvant pembrolizumab. The primary outcomes were 5-year overall survival (OS), 5-year recurrence-free survival (RFS), and recurrence patterns. RESULTS: We report updated results at 5 years of follow-up with a median follow-up of 61.9 months. No deaths occurred in patients with a major pathological response (MPR, <10% viable tumor) or complete pathological response (pCR, no viable tumor) (n = 8), compared to a 5-year OS of 72.8% for the remainder of the cohort (P = 0.12). Two of eight patients with a pCR or MPR had a recurrence. Of the patients with >10% viable tumor remaining, 8 of 22 patients (36%) had a recurrence. Additionally, the median time to recurrence was 3.9 years for patients with ≤10% viable tumor and 0.6 years for patients with >10% viable tumor (P = 0.044). CONCLUSIONS: The 5-year results from this trial represent the longest follow-up of a single-agent neoadjuvant PD-1 trial to date. Response to neoadjuvant therapy continues to be an important prognosticator with regard to OS and RFS. Additionally, recurrences in patients with pCR occur later and are salvageable, with a 5-year OS of 100%. These results demonstrate the long-term efficacy of single-agent neoadjuvant/adjuvant PD-1 blockade in patients with a pCR and the importance of long-term follow-up for these patients. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02434354.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Sharon CE, Tortorello GN, Ma KL, et al. Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma. Ann Oncol. 2023. PMID: 37414215. doi:10.1016/j.annonc.2023.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。